Hematologic Toxicity
| Patient code | BsmAb (mg/m2) | Group | Activity level (GBq/m2) | Injected activity (GBq) | Grade | Nadir (d) | Duration of nadir (d) |
|---|---|---|---|---|---|---|---|
| 01-16 | 75 | A | 1.8 | 3.0 | II (WBC), I (platelets) | 41, 31 | ND, 11 |
| 01-17 | 75 | A | 1.8 | 3.0 | II (WBC), I (platelets) | 44, 31 | 8, 13 |
| 01-18 | 75 | A | 1.8 | 3.2 | II (WBC), II (platelets) | 43, 28 | 6, 8 |
| 02-29 | 75 | A | 1.8 | 2.5 | I (platelets) | 28 | 6 |
| 03-25 | 75 | A | 2.3 | 4.3 | IV (WBC), III (platelets) | 37, 27 | 3, 31 |
| 01-19 | 75 | B | 1.8 | 2.8 | III (WBC), III (platelets) | 41, 28 | 15, 28 |
| 01-20 | 75 | B | 1.8 | 3.1 | III (WBC), III (platelets) | 42, 29 | 6, 27 |
| 01-21 | 75 | B | 1.8 | 2.4 | IV (WBC), III (platelets) | 36, 23 | 13, 64 |
| 01-23 | 75 | B | 1.8 | 2.7 | II (WBC), I (platelets) | 41, 41 | 15, 15 |
| 01-26 | 75 | B | 1.8 | 2.6 | I (WBC) | 27 | 31 |
| 01-27 | 75 | B | 1.8 | 2.9 | III (WBC), III (platelets) | 35, 28 | 6, 13 |
| 01-24 | 40 | A | C | 1.9 | ND | ||
| 01-28 | 40 | A | 2.3 | 3.9 | 0 | ||
| 01-30 | 40 | A | 2.3 | 4.3 | II (WBC), II (platelets) | 29, 29 | 8, 8 |
| 03-31 | 40 | A | 2.3 | 4.2 | 0 | ||
| 02-32 | 40 | A | 2.3 | 3.9 | 0 | ||
| 01-35 | 40 | A | C | 2.2 | 0 | ||
| 01-36 | 40 | A | 2.9 | 5.5 | III (WBC), II (platelets) | 43, 35 | 8, 8 |
| 01-38 | 40 | A | 2.9 | 4.8 | I (WBC) | 43 | ND |
| 01-33 | 40 | B | 1.8 | 2.7 | III (WBC), I (platelets) | 44, 20 | 11, 14 |
| 03-34 | 40 | B | 1.8 | 2.6 | IV (WBC), III (platelets) | 30, 30 | 6, 6 |
| 03-37 | 40 | B | 1.8 | 2.6 | ND |
Group A = non-MTC patients; WBC = white blood cells; ND = not done; Group B = MTC patients; C = compassionate treatment.